TWI854995B - 雜環化合物 - Google Patents

雜環化合物 Download PDF

Info

Publication number
TWI854995B
TWI854995B TW108132216A TW108132216A TWI854995B TW I854995 B TWI854995 B TW I854995B TW 108132216 A TW108132216 A TW 108132216A TW 108132216 A TW108132216 A TW 108132216A TW I854995 B TWI854995 B TW I854995B
Authority
TW
Taiwan
Prior art keywords
mhz
nmr1
compound
halogen
ring
Prior art date
Application number
TW108132216A
Other languages
English (en)
Chinese (zh)
Other versions
TW202035423A (zh
Inventor
大達一弘
藤森悠介
牧田直也
古関教孝
林秀樹
坂元裕樹
峰野胡桃
多賀亮介
Original Assignee
日商大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大塚製藥股份有限公司 filed Critical 日商大塚製藥股份有限公司
Publication of TW202035423A publication Critical patent/TW202035423A/zh
Application granted granted Critical
Publication of TWI854995B publication Critical patent/TWI854995B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW108132216A 2018-09-07 2019-09-06 雜環化合物 TWI854995B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-167488 2018-09-07
JP2018167488 2018-09-07

Publications (2)

Publication Number Publication Date
TW202035423A TW202035423A (zh) 2020-10-01
TWI854995B true TWI854995B (zh) 2024-09-11

Family

ID=68063002

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108132216A TWI854995B (zh) 2018-09-07 2019-09-06 雜環化合物

Country Status (12)

Country Link
US (2) US11932657B2 (https=)
EP (1) EP3847176A1 (https=)
JP (1) JP7448527B2 (https=)
KR (1) KR102810086B1 (https=)
CN (1) CN112654627A (https=)
AU (2) AU2019335968B2 (https=)
CA (1) CA3109610A1 (https=)
EA (1) EA202190654A1 (https=)
IL (1) IL280821B2 (https=)
SG (1) SG11202101963XA (https=)
TW (1) TWI854995B (https=)
WO (1) WO2020050409A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7448527B2 (ja) 2018-09-07 2024-03-12 大塚製薬株式会社 ヘテロ環式化合物
IL291322B2 (en) 2019-12-09 2026-02-01 Otsuka Pharma Co Ltd Acrylamide compounds
US20230279000A1 (en) 2020-02-26 2023-09-07 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN115215720B (zh) * 2021-04-19 2023-08-22 中国科学院化学研究所 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用
WO2022228399A1 (zh) * 2021-04-27 2022-11-03 山东轩竹医药科技有限公司 三并环类usp1抑制剂及其用途
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
KR20240054994A (ko) * 2021-09-02 2024-04-26 재규어 테라퓨틱스 피티이 리미티드 AhR 시그널링의 조절에 유용한 화합물
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
JP7527515B1 (ja) * 2022-10-29 2024-08-02 松本油脂製薬株式会社 弾性繊維用処理剤及びその利用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN103313989B (zh) 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
DK3312270T3 (da) 2015-06-16 2020-10-12 Univ Kyoto Fremgangsmåde til fremstilling af plader med høj ydeevne
WO2018195397A2 (en) * 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
WO2019167973A1 (en) 2018-03-01 2019-09-06 Kyoto University Cell cycle progression inhibitor
JP7448527B2 (ja) 2018-09-07 2024-03-12 大塚製薬株式会社 ヘテロ環式化合物
IL291322B2 (en) 2019-12-09 2026-02-01 Otsuka Pharma Co Ltd Acrylamide compounds
JP2022188761A (ja) 2021-06-09 2022-12-21 大塚製薬株式会社 窒素原子含有複素環化合物を用いる血小板産生方法

Also Published As

Publication number Publication date
AU2019335968A1 (en) 2021-05-06
US20210340157A1 (en) 2021-11-04
CN112654627A (zh) 2021-04-13
WO2020050409A1 (en) 2020-03-12
CA3109610A1 (en) 2020-03-12
IL280821B1 (en) 2024-10-01
EA202190654A1 (ru) 2021-05-27
KR102810086B1 (ko) 2025-05-21
IL280821B2 (en) 2025-02-01
US11932657B2 (en) 2024-03-19
SG11202101963XA (en) 2021-03-30
NZ774547A (en) 2025-10-31
EP3847176A1 (en) 2021-07-14
US20240208999A1 (en) 2024-06-27
TW202035423A (zh) 2020-10-01
JP7448527B2 (ja) 2024-03-12
JP2021536482A (ja) 2021-12-27
AU2024203760A1 (en) 2024-06-20
KR20210056373A (ko) 2021-05-18
IL280821A (en) 2021-04-29
AU2019335968B2 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
TWI854995B (zh) 雜環化合物
JP7653362B2 (ja) 二環式化合物
RU2538200C2 (ru) ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ИХ СОДЕРЖАЩАЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С КИНАЗОЙ mTOR ИЛИ КИНАЗОЙ PI3K
JP6445574B2 (ja) ブロモドメイン阻害剤
AU2014340110B2 (en) Inhibitors of human immunodeficiency virus replication
AU2024278273A1 (en) Compounds
US20120329784A1 (en) Compounds and methods
WO2009085256A1 (en) Anti-hiv compounds
WO2010102154A2 (en) Biaryl oxyacetic acid compounds
CN112469714B (zh) 作为端锚聚合酶抑制剂的1,2,4-三唑衍生物
EA046483B1 (ru) Гетероциклическое соединение
CA3155466A1 (en) Acrylamide compounds
HK40048052A (zh) 杂环化合物
RU2838187C2 (ru) Соединения
NZ755709A (en) Aryl hydrocarbon receptor (ahr) modulator compounds